Rep. April McClain Delaney Sells Off Shares of STERIS plc (NYSE:STE)

Representative April McClain Delaney (Democratic-Maryland) recently sold shares of STERIS plc (NYSE:STE). In a filing disclosed on September 09th, the Representative disclosed that they had sold between $100,001 and $250,000 in STERIS stock on August 25th.

Representative April McClain Delaney also recently made the following trade(s):

• Sold $100,001 – $250,000 in shares of Wabtec (NYSE:WAB) on 8/25/2026.
• Sold $100,001 – $250,000 in shares of Viking (NYSE:VIK) on 8/25/2026.
• Sold $100,001 – $250,000 in shares of Trimble (NASDAQ:TRMB) on 8/25/2026.
• Sold $100,001 – $250,000 in shares of Transdigm Group (NYSE:TDG) on 8/25/2026.
• Sold $15,001 – $50,000 in shares of Tractor Supply (NASDAQ:TSCO) on 8/25/2026.
• Sold $15,001 – $50,000 in shares of Middleby (NASDAQ:MIDD) on 8/25/2026.
• Sold $15,001 – $50,000 in shares of Teledyne Technologies (NYSE:TDY) on 8/25/2026.
• Sold $100,001 – $250,000 in shares of Somnigroup International (NYSE:SGI) on 8/25/2026.
• Sold $100,001 – $250,000 in shares of Signet Jewelers (NYSE:SIG) on 8/25/2026.
• Sold $100,001 – $250,000 in shares of Paychex (NASDAQ:PAYX) on 8/25/2026.

STERIS Stock Performance

STE stock opened at $211.10 on Friday. The company has a quick ratio of 1.35, a current ratio of 1.91 and a debt-to-equity ratio of 0.23. The business’s fifty day simple moving average is $225.55 and its two-hundred day simple moving average is $221.14. STERIS plc has a twelve month low of $195.14 and a twelve month high of $269.44. The firm has a market cap of $20.58 billion, a price-to-earnings ratio of 25.81 and a beta of 0.91.

STERIS (NYSE:STE) last posted its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.59 EPS for the quarter, topping analysts’ consensus estimates of $2.49 by $0.10. The firm had revenue of $1.49 billion for the quarter, compared to analysts’ expectations of $1.49 billion. STERIS had a net margin of 13.34% and a return on equity of 14.34%. The business’s revenue for the quarter was up 7.3% on a year-over-year basis. During the same period in the prior year, the business posted $2.34 earnings per share. STERIS has set its FY 2027 guidance at 11.000-11.300 EPS. Analysts predict that STERIS plc will post 11.09 earnings per share for the current year.

STERIS Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 25th. Shareholders of record on Friday, September 4th will be given a $0.69 dividend. This is a boost from STERIS’s previous quarterly dividend of $0.63. The ex-dividend date of this dividend is Friday, September 4th. This represents a $2.76 annualized dividend and a yield of 1.3%. STERIS’s dividend payout ratio is currently 33.74%.

Insider Activity

In other news, VP John Zangerle sold 1,419 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $209.28, for a total transaction of $296,968.32. Following the transaction, the vice president directly owned 35,259 shares in the company, valued at $7,379,003.52. The trade was a 3.87% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mohsen Sohi sold 4,058 shares of the firm’s stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $235.78, for a total transaction of $956,795.24. Following the sale, the director owned 24,305 shares of the company’s stock, valued at $5,730,632.90. This represents a 14.31% decrease in their position. The disclosure for this sale is available in the SEC filing. 1.12% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. UBS Group reduced their target price on shares of STERIS from $275.00 to $270.00 and set a “buy” rating on the stock in a research report on Friday, August 7th. Weiss Ratings reissued a “hold (c)” rating on shares of STERIS in a research note on Monday, August 24th. Wall Street Zen raised STERIS from a “hold” rating to a “buy” rating in a research report on Sunday, August 9th. Finally, Piper Sandler reissued an “overweight” rating and set a $275.00 price target (up from $270.00) on shares of STERIS in a research report on Friday, August 7th. Three research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $271.33.

Institutional Trading of STERIS

A number of hedge funds have recently added to or reduced their stakes in STE. California State Teachers Retirement System raised its position in shares of STERIS by 20,515.0% in the second quarter. California State Teachers Retirement System now owns 35,267,316 shares of the medical equipment provider’s stock worth $7,426,239,000 after acquiring an additional 35,096,240 shares during the period. State Street Corp grew its holdings in STERIS by 6.0% in the fourth quarter. State Street Corp now owns 4,614,840 shares of the medical equipment provider’s stock valued at $1,169,957,000 after purchasing an additional 260,001 shares during the period. Wellington Management Group LLP increased its position in shares of STERIS by 21.9% in the second quarter. Wellington Management Group LLP now owns 3,502,897 shares of the medical equipment provider’s stock valued at $737,605,000 after buying an additional 629,532 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of STERIS by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 2,523,620 shares of the medical equipment provider’s stock worth $637,259,000 after buying an additional 14,151 shares during the period. Finally, Orbis Allan Gray Ltd grew its stake in STERIS by 5.6% in the 4th quarter. Orbis Allan Gray Ltd now owns 2,249,511 shares of the medical equipment provider’s stock valued at $570,296,000 after acquiring an additional 120,200 shares during the period. 94.69% of the stock is owned by hedge funds and other institutional investors.

About Representative McClain Delaney

April McClain-Delaney (Democratic Party) is a member of the U.S. House, representing Maryland’s 6th Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

McClain-Delaney (Democratic Party) is running for re-election to the U.S. House to represent Maryland’s 6th Congressional District. She declared candidacy for the 2026 election.

April McClain-Delaney grew up in Buhl, Idaho, where her father was a potato farmer. She obtained her bachelor’s degree in communications from Northwestern University in 1986 and her law degree from Georgetown Law Center in 1989. McClain-Delaney worked in communications law, first with the satellite firm Orion Network Systems and later as the Washington director for Common Sense Media, a nonprofit focused on technology and children. In 2022, McClain-Delaney joined the U.S. Department of Commerce under President Joe Biden (D) as deputy assistant secretary for communications and information. McClain-Delaney served on the board of the Georgetown University Law Center, the International Center for Research on Women, and the Northwestern University School of Communications.

STERIS Company Profile

STERIS plc (NYSE: STE) is a global provider of products and services designed to support infection prevention, sterilization, surgical procedures and other critical healthcare and life sciences activities. The company serves hospitals, ambulatory surgery centers, dental practices, pharmaceutical and biotechnology manufacturers, medical device companies, and research organizations.

Its offerings include sterilizers, washers, surgical tables and lights, operating-room equipment, endoscopy products, infection-prevention consumables, and related maintenance and technical services.